Mylan and Biocon ended 2017 with more positive news for their biosimilar program; on December 29, 2017, the partnership announced that Brazil’s National Sanitary Surveillance Agency (ANVISA) had approved their trastuzumab biosimilar.
Mylan and Biocon ended 2017 with more positive news for their biosimilar program; on December 29, 2017, the partnership announced that Brazil’s National Sanitary Surveillance Agency (ANVISA) had approved their trastuzumab biosimilar for the treatment of overexpressing HER2-positive metastatic breast cancer, HER2-positive early breast cancer and HER2-positive advanced gastric cancer. The drug, which will be sold under the brand name Zedora, is the first biosimilar trastuzumab to be approved in Brazil.
In a statement, Mylan’s CEO, Heather Bresch, highlighted the fact that the biosimilar could bring about greater patient access to biologic treatment for cancer: “The number of women diagnosed with breast cancer in Brazil is increasing. Sadly, many of the women with HER2-positive metastatic breast cancer in Brazil do not have access to [trastuzumab] through the country's public health system. The approval of Zedora…is an important step in our efforts to increase access to this critical product for patients with certain breast and gastric cancers and reduce the overall financial burden for health systems around the world."
The ANVISA approval was granted through Mylan and Biocon’s Brazilian partner, Libbs Farmaceutica. Libbs is a pharmaceutical company that currently markets approximately 90 drug brands in 200 presentations for indications in gynecology, neurology, cardiology, oncology, and dermatology. The company’s biotechnology unit, Biotech, launched in 2016, is responsible for the production of its monoclonal antibodies.
Earlier in December 2017, the Mylan and Biocon gained FDA clearance for the same drug, which will be marketed in the United States under the brand name Ogivri. The FDA approval was the first for a biosimilar trastuzumab, and the second for an anticancer therapy in the United States.
The partnership has also re-submitted an application for the drug to the European Medicines Agency (EMA) after its first application was withdrawn as the companies awaited re-inspection of a manufacturing facility in India. Should the Mylan and Biocon product gain EMA clearance, the drug will eventually compete with Celltrion’s recently EMA-approved biosimilar trastuzumab, Herzuma, as well as Samsung Bioepis’ EMA-approved product, Ontruzant.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
FDA Draft Guidance Removes Switching Study Requirements for Biosimilar Interchangeability
June 20th 2024The FDA has issued an update to its guidance on requiring switching study data for biosimilars to be granted interchangeability, citing new science that shows these studies aren’t needed to establish biosimilar safety.
British Columbia’s Biosimilar Switching Program Saves $732 Million in 5 Years
June 18th 2024British Columbia's 2019 Biosimilars Initiative, which transitioned over 40,000 patients from costly reference biologics to biosimilars, saved around $732 million in 5 years, maintained comparable health outcomes, and reinvested the savings to improve the province's public payer program.